Investors take note! Acasti Pharma (NASDAQ: NASDAQ:) has just been reaffirmed with a Buy rating and a $12.00 price target by H.C. Wainwright, a leading financial firm. This news comes as Acasti announces the completion of enrollment for its STRIVE-ON trial for GTX-104, a potential game-changer in treating aneurysmal subarachnoid hemorrhage (aSAH).
The biopharmaceutical company has reported significant progress in its pivotal safety trial, with enrollment completing ahead of schedule. With top-line data expected by February, H.C. Wainwright projects a potential FDA approval for GTX-104 by April 2026, signaling a new standard of care for aSAH patients.
Analysts anticipate a mid-2026 launch for GTX-104, with projected peak sales exceeding $130 million. This optimistic outlook is based on the drug's market potential in the U.S., where thousands of aSAH cases occur annually. Moreover, there is additional growth potential outside the U.S. market.
H.C. Wainwright views the STRIVE-ON trial as a low-risk study, highlighting the safety profile of GTX-104 compared to existing treatments. The firm also believes that the FDA approval process for GTX-104 is relatively low-risk, given the precedent set by previous nimodipine formulations.
Overall, Acasti Pharma's promising developments and potential market impact make it a stock to watch for savvy investors looking to capitalize on the future of healthcare innovation.